Aclaris Therapeutics Stock News

HC Wainwright reiterated their buy rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research note published on Monday, TipRanks reports. They currently have a $50.00 price objective on the biotechnology companys stock. Separately, SVB Leerink reiterated a buy rating and set a $26.00 target price on shares of Aclaris Therapeutics in a research note [] The post Aclaris Therapeutics (NASDAQ:ACRS) Earns Buy Rating from HC Wainwright appeared first on ETF Daily News .

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock analysts at SVB Leerink issued their FY2024 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Tuesday, December 7th. SVB Leerink analyst T. Smith forecasts that the biotechnology company will post earnings of ($1.85) per share for the []

WAYNE, Pa., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammator

WAYNE, Pa., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the publication of preclinical research of zunsemetinib in pancreatic cancer in the peer-reviewed journal Science Translational Medicine , on December 1, 2021.

Brokerages expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report earnings per share (EPS) of ($0.36) for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Aclaris Therapeutics earnings. The lowest EPS estimate is ($0.39) and the highest is ($0.34). Aclaris Therapeutics reported earnings of ($0.31) per share during the same quarter []

Analysts expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to announce $1.87 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Aclaris Therapeutics earnings. The lowest sales estimate is $1.70 million and the highest is $2.40 million. Aclaris Therapeutics posted sales of $1.58 million in the same quarter last year, [] The post Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Expected to Announce Quarterly Sales of $1.87 Million appeared first on ETF Daily News .

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has earned an average rating of Buy from the five brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued []

Charles Schwab Investment Management Inc. boosted its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 583.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 107,838 shares of the biotechnology companys stock after buying an additional 92,049 shares during the quarter. Charles Schwab Investment Management []

State Street Corp grew its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 454.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,070,214 shares of the biotechnology companys stock after acquiring an additional 877,272 shares during the quarter. State []

Investigational New Drug Application for ATI-2138 Allowed

Investigational New Drug Application for ATI-2138 Allowed

Marriott to integrate Amadeus’ CRS solution - Hotel Business | Hotel Business Marriott International has an agreement with Amadeus to deploy the Amadeus Central Reservations System (ACRS) to modernize its reservation infrastructure in the coming years. Integrating the ACRS will ultimately replace Marriott’s proprietary reservations system and expand its commerce capabilities including enabling travelers to personalize their travels by providing greater flexibility in choosing guestroom attributes and […] Marriott to integrate Amadeus’ CRS solution - Hotel Business appeared first on Hotel Business | Hotel Business - The leading source of hospitality news for owners, developers, designers, brokers, brands, management companies, lenders, REITs & asset managers.

HC Wainwright reiterated their buy rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research report released on Monday morning, PriceTargets.com reports. HC Wainwright currently has a $49.00 target price on the biotechnology companys stock. ACRS has been the subject of a number of other research reports. SVB Leerink reaffirmed a buy rating and issued []

Aclaris Therapeutics (NASDAQ:ACRS)s stock had its buy rating reaffirmed by research analysts at HC Wainwright in a research report issued on Monday, TipRanks reports. They presently have a $49.00 price objective on the biotechnology companys stock. HC Wainwrights target price indicates a potential upside of 229.74% from the companys current price. Several other brokerages also []

WAYNE, Pa., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory